Role_of_interferons_in_the_therapy_of_melanoma._A_range_of_potent_immunoregulatory_molecules_termed_cytokines_has_become_available_for_the_therapy_of_human_melanoma._Among_the_cytokines,_the_interferons_(IFN)_have_been_examined_in_great_depth_for_the_therapy_of_melanoma._IFN_are_able_to_modulate_host_effector_cell_function,_including_the_tumor_cytolytic_function_of_lymphocytes_and_monocytes._IFN_also_have_the_capacity_to_regulate_the_distribution_of_circulating_immunoregulatory_(T)_lymphocytes_and_the_expression_of_tumor_cell_surface_antigens,_as_well_as_class_I_and_II_products_of_the_major_histocompatibility_locus._These_activities_of_the_IFN_have_led_to_their_early_application_for_treatment_of_human_melanoma._The_empirical_evidence_that_IFN_alpha_exerts_clinically_significant_anti-tumor_effects_against_melanoma_is_reviewed,_and_evolving_status_of_adjuvant_trials_of_IFN_alpha_and_gamma_is_noted._New_indirect_host-mediated_anti-tumor_activities_that_may_potentially_be_manifest_by_IFN_have_yet_to_be_fully_harnessed._The_opportunity_to_obtain_meaningful_anti-tumor_activity_in_advanced_disease_or_adjuvant_settings,_at_dose_ranges_below_those_which_are_toxic_(conventional_maximal_tolerable),_are_at_hand._The_U.S._cooperative_groups_Eastern_Cooperative_Oncology_Group_(ECOG),_Cancer_and_Leukemia_Group_B_(CALGB),_and_South_West_Oncology_Group_(SWOG)_are_studying_IFN_gamma_in_pursuit_of_this_goal_in_advanced_and_adjuvant_settings_for_melanoma_and_other_tumors._The_determination_of_the_clinical_role_of_IFN_as_biologic_response_modifiers_demands_equal_commitment_to_the_clinical_assessment_of_immunobiologic_mechanisms_and_anti-tumor_effects._The_immunologic_assessment_of_IFN_and_a_number_of_other_cytokines_is_a_major_focus_of_the_Pittsburgh_Cancer_Institute._Regional_delivery_of_cytokines_such_as_interleukin-2_(IL-2)_may_be_the_most_appropriate_and_least_toxic_approach,_given_their_half-life._Regional_therapy_by_the_intralesional_route_has_yielded_enhanced_activity_for_a_range_of_biologics,_including_bacillus_Calmette-Guerin_(BCG),_IL-2,_and_tumor_necrosis_factor_(TNF)._Intralymphatic_therapy_with_methanol_extraction_residue_of_BCG_(MER-BCG)_has_been_tested,_and_trials_are_now_in_progress_with_IL-2_to_assess_the_optimal_dosage_by_this_route._It_is_likely_that_the_optimal_role_of_IFN_and_other_cytokines_will_be_found_in_combination_with_one_another,_and_with_different_biologic_modalities_such_as_monoclonal_antibodies_and_vaccines,_to_allow_expansion_and_heightened_activity_of_the_desired_effector_cell_populations_in_the_host._Enhanced_host_toxicities,_as_well_as_anti-tumor_effects,_may_require_that_special_attention_be_devoted_to_optimal_sequence_of_administration_to_enhance_the_therapeutic_index.